[Role of Dipeptidyl peptidase inhibitors in lung ischemia-reperfusion injury].

Lung ischemia-reperfusion injury (LIRI)is a common complication after lung transplantation and cardiopulmonary bypass. It is an important factor affecting the success rate of transplantation. Its specific pathogenesis has not yet been fully elucidated. It is very significant to find the targets and drugs for the prevention and treatment of LIRI in order to improving the utilization rate of "marginal donor lung" and the long-term survival rate of lung transplant patients. Dipeptidyl peptidase 4(DPP4) inhibitors are a class of oral hypoglycemic agents. Previous studies have shown that DPP4 inhibitors have a variety of pharmacological activities, including anti-inflammatory, anti-fibrotic, immunomodulatory and other extrapancreatic functions. Recent studies have shown that DPP4 inhibitors may alleviate LIRI through various mechanisms, including inhibiting inflammatory responses, reducing oxidative stress, regulating blood glucose levels, and activating autophagy. This article reviewed the clinical and preclinical applications and mechanisms of DPP4 inhibitors in LIRI.肺缺血再灌注损伤（LIRI）是肺移植、体外循环术后常见并发症，是影响移植成功率的重要因素，但其具体发病机制目前尚未被完全阐明。寻找防治LIRI的靶点和药物，对提高“边缘性供肺”利用率和肺移植患者的远期生存率具有重要的临床意义。二肽基肽酶4（DPP4）抑制剂是一类口服降糖药，既往研究显示DPP4抑制剂具有多种药理活性，包括抗炎、抗纤维化、免疫调节等多种胰腺外功能。最近的研究显示DPP4抑制剂可能通过抑制炎症反应、减轻氧化应激、调控血糖水平和激活自噬等多种机制减轻LIRI。本文就DPP4抑制剂在LIRI中的临床及临床前应用和作用机制进行综述。.